文献

J-GLOBAL ID：201802276878272615   整理番号：18A0464479

スティーブンス・ジョンソン症候群/中毒性表皮壊死症への遺伝的素因の研究動向【Powered by NICT】

Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis

著者 (31件)： Manolio Teri A. (Division of Genomic Medicine, National Human Genome Research Institute, Bethesda, Maryland, USA) ,  Hutter Carolyn M. (Division of Genomic Medicine, National Human Genome Research Institute, Bethesda, Maryland, USA) ,  Avigan Mark (Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA) ,  Cibotti Ricardo (Division of Skin and Rheumatic Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA) ,  Davis Robert L. (Center for Biomedical Informatics, University of Tennessee Health Science Center, Memphis, Tennessee, USA) ,  Denny Joshua C. (Departments of Biomedical Informatics and Medicine, Vanderbilt University, Nashville, Tennessee, USA) ,  Grenade Lois La (Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA) ,  Wheatley Lisa M. (Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA) ,  Carrington Mary N. (Cancer and Inflammation Program, Laboratory of Experimental Immunology, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA and Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA) ,  Chantratita Wasun (Medical Genomic Center, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand) ,  Chung Wen-Hung (Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospitals, Taipei, Linkou, and Keelung, and College of Medicine, Chang Gung University, Taoyuan, Taiwan) ,  Dalton Andrea D. (Stevens-Johnson Syndrome Foundation, Westminster, Colorado, USA) ,  Hung Shuen-Iu (Institute and Department of Pharmacology, National Yang-Ming University, Taipei, Taiwan) ,  Lee Ming Ta Michael (Genomic Medicine Institute, Geisinger Health System, Danville, Pennsylvania, USA) ,  Leeder J. Steven (Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children’s Mercy Hospital, Kansas City, Missouri, USA) ,  Lertora Juan J.L. (Clinical Pharmacology Program, National Institutes of Health Clinical Center, Bethesda, Maryland, USA) ,  Mahasirimongkol Surakameth (Medical Genetics Center, Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand) ,  McLeod Howard L. (DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida, USA) ,  Mockenhaupt Maja (Dokumentationszentrum schwerer Hautreaktionen (dZh), Department of Dermatology, Medical Center and Medical Faculty - University of Freiburg, Freiburg, Germany) ,  Pacanowski Michael (Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA) ,  Phillips Elizabeth J. (Department of Medicine, Pharmacology, Oates Institute for Experimental Therapeutics, Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee, USA) ,  Phillips Elizabeth J. (Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia) ,  Pinheiro Simone (Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA) ,  Pirmohamed Munir (Institute of Translational Medicine, University of Liverpool, Liverpool, UK) ,  Sung Cynthia (Duke-National University of Singapore Medical School, Singapore) ,  Suwankesawong Wimon (Health Product Vigilance Center, Thai Food and Drug Administration, Nonthaburi, Thailand) ,  Trepanier Lauren (School of Veterinary Medicine, University of Wisconsin Madison, Madison, Wisconsin, USA) ,  Tumminia Santa J. (Office of the Director, National Eye Institute, Bethesda, Maryland, USA) ,  Veenstra David (Department of Pharmacy, University of Washington, Seattle, Washington, USA) ,  Yuliwulandari Rika (YARSI Research Institute, YARSI University, Jakarta, Indonesia) ,  Shear Neil H. (Department of Medicine (Dermatology and Clinical Pharmacology and Toxicology), University of Toronto, Toronto, Canada)
資料名： Clinical Pharmacology & Therapeutics  (Clinical Pharmacology & Therapeutics)
巻： 103  号： 3  ページ： 390-394  発行年： 2018年 
JST資料番号： A0721B  ISSN： 0009-9236  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： スティーブンス・ジョンソン症候群/中毒性表皮壊死症(SJS/TEN)は有害薬物反応の最も破壊的な(ADR)の一つであり,最近までは本質的に予測できない。薬剤誘発性SJS/十のいくつかのリスク対立遺伝子と還元発生率のスクリーニングの有効性の実証の発見により,ステージは,リスク集団における予防戦略の実行のための設定した。しかし多くは一般的に用いられる薬剤のこの潜在的に致命的な合併症について学んだされていない。Copyright 2018 Wiley Publishing Japan K.K. All Rights reserved. Translated from English into Japanese by JST.【Powered by NICT】

シソーラス用語： *対立遺伝子
準シソーラス用語： 薬物反応 ,  *遺伝素因 ,  *中毒性表皮壊死症 , 【Automatic Indexing@JST】

分類 (1件)： 代謝異常・栄養性疾患の治療  (GD05030F)

タイトルに関連する用語 (5件)： スティーブンス・ジョンソン症候群 ,  中毒性表皮壊死症 ,  遺伝的素因 ,  研究 ,  動向